Evaluation of a new portable analyzer, HemoCue < sup > ® < /sup > Hb801, for hemoglobin point-of-care testing

Ann Biol Clin (Paris). 2024 Apr 19;82(1):103-111. doi: 10.1684/abc.2024.1868.ABSTRACTThe use of portable hemoglobin measuring devices is widespread. In this context, the company HemoCue® has put on the market a new device, the Hb801. It uses a whole blood absorbance measurement method and not the azidmethemoglobin measurement method used by HemoCue's older devices. We evaluated this new equipment on EDTA venous blood. Hb801 is lightweight, compact, requires a volume of 10 μL of blood and renders its result in less than a second. The repeatability and intermediate precision are close to the values expected according to Ricos, with coefficients of variation respectively for a low level of hemoglobin: 2.1% and 1.9%, for an average level: 0.8% and 1.5% and for a high level: 1.5% and 1.3%. Comparison to our laboratory reference method (XN-10 Sysmex®) and HemoCue® Hb201+ was performed on 96 samples. Bias (SD) found were: XN-10: +0.42 g/dL (0.17), HemoCue® Hb201+: +0.17 g/dL (0.41). Clinically acceptable performance (within ± 1 g/dL of reference hemoglobin) was high: 93.8%. In the end, this device seems to us to be suitable for hemoglobin point-of-care testing.PMID:38638023 | DOI:10.1684/abc.2024.1868
Source: Annales de Biologie Clinique - Category: Biochemistry Authors: Source Type: research